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Abstract
We infected mice with the 2009 influenza A pandemic virus (H1N1pdm09), boosted with an 
inactivated vaccine, and cloned immunoglobulins (Igs) from HA-specific B cells. Based on the 
redundancy in germline gene utilization, we inferred that between 72–130 unique IgH VDJ and 35 
different IgL VJ combinations comprised the anti-HA recall response. The IgH VH1 and IgL 
VK14 variable gene families were employed most frequently. A representative panel of antibodies 
were cloned and expressed to confirm reactivity with H1N1pdm09 HA. The majority of the 
recombinant antibodies were of high avidity and capable of inhibiting H1N1pdm09 
hemagglutination. Three of these antibodies were subtype-specific cross-reactive, binding to the 
HA of A/South Carolina/1/1918(H1N1), and one further reacted with A/swine/Iowa/
15/1930(H1N1). These results help define the genetic diversity of the influenza anti-HA antibody 
repertoire profile induced following infection and vaccination, which may facilitate the 
development of influenza vaccines that are more protective and broadly neutralizing.
Importance—Protection against influenza viruses is mediated mainly by antibodies, and in most 
cases this antibody response is narrow, only providing protection against closely-related viruses. In 
spite of this limited range of protection, recent findings indicate individuals immune to one 
influenza virus may contain antibodies (generally a minority of the overall response) that are more 
broadly reactive. These findings have raised the possibility that influenza vaccines could induce a 
more broadly protective response, reducing the need for frequent vaccine strain changes. However, 
interpretation of these observations is hampered by the lack of quantitative characterization of the 
antibody repertoire. In this study, we used single-cell cloning of influenza HA-specific B cells to 
assess the diversity and nature of the antibody response to influenza hemagglutinin in mice. Our 
findings help put bounds on the diversity of the anti-hemagglutinin antibody response, as well as 
characterizing the cross-reactivity, affinity, and molecular nature of the antibody response.
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Influenza viruses are common pathogens of humans and animals. In humans, influenza virus 
infections cause substantial morbidity and mortality through seasonal epidemics and 
occasional pandemics (1, 2). Vaccination remains the key component of public health 
protection against influenza virus infection. However, durable protection is limited by the 
ability of influenza virus to undergo rapid genetic and antigenic change, allowing it to 
escape from pre-existing immunity. As a result, influenza vaccines require updating on a 
regular basis (3).
Antibodies that target the principal viral surface protein, hemagglutinin (HA), play a major 
role in protection against influenza virus infection and provide the basis for current vaccine 
design and the tests by which vaccine efficacy is assessed (4). HA is a trimeric glycoprotein 
consisting of the membrane-distal globular head and the stalk region. The head is 
responsible for receptor binding, while the HA2 subunit is required for viral fusion with 
cellular membranes. Antibodies that bind to the globular head of HA and block receptor 
binding can be detected by the hemagglutination inhibition (HI) assay, and HI antibody 
threshold titers ≥32 are associated with a reduction in the risk of influenza infection (5). 
There are four or five antigenic sites in the globular head region of the HA (6, 7) and 
antibodies binding to these antigenic sites generally have virus-neutralizing activity, but non-
neutralizing globular-head binding antibodies also have been described (8–12). Antibodies 
binding outside these antigenic sites, including to the stalk region of HA, have also been 
identified. Some of these antibodies confer protection against infection, either by directly 
blocking virus infectivity or by playing a role in other functions of the immune system, such 
as antibody-dependent cellular cytotoxicity (ADCC)-mediated activation of NK cells (13–
15) or complement (16, 17).
Influenza virus can tolerate significant sequence variation in antigenic sites, and sequence 
changes in these regions (“antigenic drift”) often reduce binding of the existing antibody 
repertoire. Some anti-HA antibodies, however, are broadly cross-reactive, and can confer 
protection to a range of viruses within a particular HA subtype or even across subtypes. 
These antibodies have been reported to bind to conserved regions within the globular head of 
HA (18–22) or the stalk region (18, 19, 23–28).
Clearly the goal of influenza vaccination is to increase the proportion of antibodies that are 
protective, and ideally to increase the proportion that are cross-protective against multiple 
strains. Generating antibodies after vaccination that are cross-protective against antigenically 
drifted strains of the same subtype may reduce the need for frequent updates of vaccine 
strains. Furthermore, a vaccine that could elicit broadly cross-reactive antibodies that protect 
against multiple subtypes of HA would be an important public health tool in the event of a 
newly emerged virus with pandemic potential. However, without understanding the relative 
frequency of strain-specific versus cross-reactive, it is difficult to preferentially stimulate an 
optimal antibody response.
Evaluating the anti-influenza repertoire in humans is complicated by the fact that, with 
increasing age, individuals are repeatedly exposed to antigenically diverse influenza viruses, 
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including both different subtypes and drifted strains within a subtype. Exposure to any 
particular HA is likely to preferentially stimulate and expand previously primed B cells, 
eclipsing the stimulation of naive B cells and thereby potentially impairing the generation of 
strain-specific, high-affinity antibodies that provide a more protective response.
At the molecular level, mouse antibody responses are generally similar to that of humans, 
but the exposure of laboratory mice to influenza viruses can be controlled. To understand the 
antibody repertoire arising from infection with influenza virus, we infected naïve C57BL/6 
mice with the 2009 pandemic influenza A virus (H1N1pdm09) and boosted them with an 
inactivated influenza vaccine. B cells specific to HA were purified, and the immunoglobulin 
(Ig) heavy and light chain variable regions were cloned from single B cells to characterize 
the diversity and specificity of the anti-HA antibody repertoire.
Materials and Methods
Cells, virus, and recombinant hemagglutinin
Human embryonic kidney 293T cells (293T) were obtained from ATCC (Manassas, VA) and 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
calf serum (Thermo Fisher Scientific, Pittsburg, PA) and penicillin streptomycin (Invitrogen, 
Carlsbad, CA).
Influenza viruses were grown in embryonated chicken eggs and titers were determined on 
MDCK cells by plaque assay. Table 1 summarizes the viruses and recHAs used, including 
the abbreviations used in this report.
The full-length recombinant his-tagged HA (recHA) from CA/04(H1pdm) and DE/68(H13) 
used for fluorescence-activated cell sorting (FACS) analysis were obtained from the 
Influenza Reagent Resource (IRR) (Manassas, VA). For ELISA studies, full-length recHA 
from CA/04(H1pdm), SC/1918(H1), IA/1930(H1) and Bris/59(H1) were also obtained from 
IRR (Manassas, VA). For kinetic studies, the CA/07(H1pdm) recHA protein was produced 
in a baculovirus expression system as previously described (29).
Inoculation of mice and isolation of leukocytes
All animal experiments were performed in accordance with the guidelines of the CDC 
Institutional Animal Care and Use Committee in an Association for the Assessment and 
Accreditation of Laboratory Animal Care accredited facility. Female 8–12 week old 
C57BL/6 mice were anesthetized by isoflurane inhalation and inoculated intranasally with 
50 μL containing 104–105 plaque-forming units of OH/07(H1pdm) diluted in sterile PBS, 
pH 7.4. Three to four weeks post-infection, mice were boosted by IP injection with 200 μL 
of the 2011/12 trivalent inactivated influenza vaccine (TIV) (Fluarix: GSK, Research 
Triangle Park, NC), which contained the HA from CA/07(H1pdm), VIC/210(H3), and BR/
60(B) viruses (6 μg of each HA). Three days post-boost, four mice per group were 
euthanized by isoflurane overdose followed by cervical dislocation, and spleens were 
harvested and pooled in order to remove inter-individual bias. In brief, the spleens were 
ground between two frosted glass slides, and the cells were dissociated through a 70-μm 
mesh strainer. Cells were then centrifuged at 550 x g for 20 min over an 18.23% histodenz 
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(Sigma-Aldrich, St Louis, MO) cushion at room temperature with the brake off. The low-
density cells were collected, washed with FACS buffer and incubated in red blood cell lysing 
media (Sigma-Aldrich) for 5 min at room temperature. The cells were again washed and 
resuspended in FACS buffer for further analysis.
Biotinylation of recHA
CA/04(H1pdm) and DE/68(H13) recHA (2 mg of each) were buffer exchanged into 0.1 M 
sodium acetate, pH 5.5 (oxidation buffer), by centrifugation in Amicon Ultra-4 desalting 
centrifugal filter units (Millipore, Billerica, MA) and diluted to a final volume of 1 ml (2 
mg/ml). The glycans on the proteins were oxidized by adding 1 ml of 20 mM sodium meta-
periodate (Sigma-Aldrich) and incubating for 30 min on ice, in the dark. The buffer was then 
exchanged to PBS, pH 7.2, in a total volume of 3.6 ml, using a desalting column. Four 
hundred μl of 50 mM Pierce Biotin-PEG4-Hydrazide in DMSO (Thermo Fisher Scientific) 
was added to the protein, which was then incubated for 2 h at room temperature with gentle 
rocking, protected from light. The protein was again buffer exchanged into 50 mM Tris-Cl, 
pH 7.4 containing 100 mM NaCl and 15 % w/v glycerol. The concentration of the protein 
was determined using the Coomassie Plus Protein Assay Reagent (Thermo Fisher 
Scientific), and the molar ratio of biotin to protein was quantified using the Pierce Biotin 
Quantitation Kit (Thermo Fisher Scientific). The protein was stored at −80 °C in single-use 
aliquots.
B cell labeling and flow cytometry
The isolated leukocytes were labeled with biotinylated HA, followed by streptavidin-APC 
(BD Biosciences). In addition, the following surface markers were used: CD3e-V450 
(500A2), CD4-V450 (RM4-5), CD8a-V450 (53-6.7), CD11b-V450 (M1/70), IgD-V450 
(11-26c.2a), Gr1-V450 (RB6-8C5), CD19-PE-Cy7 (1D3), CD138-PE (281-2) and IgM-
FITC (R6-60.2) (BD Biosciences, San Jose, CA). All staining was performed in the 
following antibody dilution buffer: Hank’s Balanced Salt Solution (HBSS) containing 5 % 
FBS (Hyclone), 10 mM of EDTA, 10mM of HEPES, 1% Fc Block (BD Biosciences, San 
Jose, CA) and 5% each of normal hamster serum, normal mouse serum and normal rat 
serum (Jackson ImmunoResearch). The optimal staining conditions identified were 5 μg/ml 
of biotinylated-HA and 1.25 μg/ml of streptavidin-APC.
Cells were analyzed using a BD FACS CANTO II, and single cell sorting was performed 
using a BD FACS Aria II. The cells were gated on FSC-A/FSC-H to remove doublets and 
FSC-A/SSC-A to remove debris. Single antigen-positive B cells were sorted based on IgM-/
CD19+/HA+ surface staining onto the 48 reaction sites of an AmpliGrid AG480F slide 
(Beckman Coulter, Houston, TX). A visual analysis of cell deposition on the AmpliGrid 
AG480F slide using a microscope was used to monitor the accuracy of the sort.
Molecular cloning of Ig genes
A Multiplex One-step RT-PCR (Qiagen, Valencia, CA) was performed directly on the slide 
in a 1 μL reaction containing 1x Qiagen RT-PCR buffer, 0.6 pmol of primer mix, 0.4 mM of 
each dNTP, 0.8 U of RNAsin and 0.04 μL of Qiagen enzyme mix. The primer mix was 
adopted from Tiller et al. with slight modifications (Supplemental Table 1) (30, 31). The 
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reactions were overlaid with 5 μL of sealing solution (Advalytix AG, Munich, Germany), 
and amplification was performed on an AmpliSpeed slide cycler (Beckman Coulter, 
Houston, TX) as follows: 58 °C for 30 min, 93 °C for 10 min, 40 cycles of 93 °C for 45 sec/
54 °C for 1 min/72 °C for 90 sec and a final incubation at 72 °C for 10 min. This initial 
reaction was transferred to a 96-well PCR plate and diluted to final volume of 10 μL with 
RNase free water to serve as template for subsequent reactions. In total, 1 μL of the 1st round 
reaction was used as a template for a semi-nested (IgH) and nested (IgK) reactions. The 
PCR was performed in 25 μL reactions as follows: 94 °C for 5 min, 35 cycles of 93 °C for 
45 sec/55 °C (IgH) or 45 °C (IgK) for 1 min/72 °C for 1.5 min and a final incubation at 
72 °C for 10 min. Amplification products were screened by agarose gel electrophoresis, and 
positive amplicons were sequenced for identification of germline variable and joining gene 
usage by the International ImMunoGeneTics information system (IMGT)(32). Second-round 
reactions were then repeated using 1 μL of the 1st round template and targeted, gene-
specific, V and J primers incorporating restriction sites for directional cloning into 
pFUSE2ss-CLIg-hG1 and pFUSE2ss-CLIg-hk expression vectors (InvivoGen, San Diego, 
CA). EcoRI and BsiWI were used for IgH and EcoRI and NheI for IgK ligations, 
respectively. TOPO cloning was used as an alternative strategy for Ig’s with internal 
restriction sites.
Recombinant monoclonal antibody production and quantification
293T cells in T160 flasks at 80% confluency were washed to remove serum IgG, and 
covered with OPTIMEM (Invitrogen, Carlsbad, CA) without serum. IgH and IgK constructs 
were co-transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions. The cell culture supernatants were harvested up to 10 days post transfection and 
concentrated using Amicon Ultra-30 Centrifugal Filter Unit (Millipore, Billerica, MA). The 
concentration of each recombinant monoclonal antibody (rmAb) was determined by ELISA, 
and all of the samples were normalized to a 25 μg/mL working stock.
ELISA
Costar Hi Bind plates (Corning Inc., Tewksbury, MA) were coated overnight with TIV or the 
individual monovalent inactivated virus constituents at 4 °C. For 2011/12 TIV, 3 μg/ml of 
total HA was adsorbed, and 1 ug/ml total HA was adsorbed for the individual vaccine 
constituents. For recHA, 1 ug/ml of respective protein was absorbed. The plates were 
blocked for 1 h with PBS/0.1 % Tween20 (PBST) containing 1.5 % BSA (blocking buffer) 
for 1 h at room temperature. All rmAb were serially titrated in blocking buffer and allowed 
to incubate for 1 h at room temperature. After three PBST washes, the wells were probed 
with goat anti-human (H&L)-HRP (Thermo Scientific) for 1 h at room temperature. The 
plates were washed three times with PBST, and the signal was developed with 1 step Turbo 
TMB-ELISA reagent (Thermo Scientific). The reactions were stopped with 1 N sulfuric 
acid, and the absorbance was read at 450 nm.
Hemagglutination inhibition assay
The indicated rmAb were tested for reactivity with the following BPL-inactivated virus 
antigens: H1N1 A/California/07/2009 NYMC X-179A (FR-187), H3N2 A/Victoria/
210/2009 X-187 (FR-644) and B/Brisbane/60/2008 (FR-47) (IRR), by hemagglutination 
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(HI) assay as previously described (33) using 4 hemagglutinating units (HAU) of antigen 
and 0.5 % turkey red blood cells.
BioLayer interferometry
The binding of each rmAb to CA/07 was analyzed by BioLayer interferometry (BLI) on an 
Octet Red instrument (Fortebio, Inc., Menlo Park, CA) according to the manufacturer’s 
instructions. The CA/07(H1pdm) recHA protein (34) was diluted to 75 μg/ml in kinetics 
buffer (KB; PBS containing 0.02 % Tween 20, 0.005 % sodium azide and 100 μg/ml bovine 
serum albumin, purchased from Fortebio as 10 x stock) and were coupled to offline (prior to 
running assay) anti-Penta-His biosensors using a Sidekick instrument (Fortebio). A twofold 
dilution series (25–0.391 μg/ml) for each rmAb in KB was prepared and analyzed, including 
a commercial anti-A/California/06/2009 (H1N1pdm09) mAb (Immune Technology Corp., 
CA) as a control. The data were analyzed using the system software and exported as a 
Microsoft Excel file for analysis and presentation in other software packages.
Alignments and phylogenetic trees
CDR3 regions were aligned using MUSCLE (35) and a maximum likelihood tree was 
generated using MEGA5 (36).
Estimates of germline diversity
To estimate the diversity of the germline population from which our samples of anti-HA 
heavy and light chains were drawn, we used the methods of Burnham and Overton (37, 38), 
Chao (39), Chao and Lee (40), Chao and Bunge (41), Wang and Lindsay (42), and Wang 
(43), as implemented in the R module SPECIES (44).
Results
Anti-HA B cell identification and purification
To induce an anti-HA response, C57BL/6 mice were administered a sub-lethal infection with 
OH/07(H1pdm), and three weeks later, the mice were boosted with 2011/2012 TIV. Three 
days post-boost, spleens from four mice were harvested and pooled. Antigen positive B cells 
(1.5–8 % of the CD19/IgM- population: (Figure 1D vs. B) were single cell-sorted onto glass 
slides based on their ability to bind CA/04(H1pdm) recHA. As a control, lymphocytes were 
stained with the distantly-related recHA of DE/68(H13) (Figure 1A, C).
Anti-HA IgH and IgL gene segment usage
The amplification of the IgH gene from the single cells yielded 54 heavy chains for which 
respective VDJH germline genes were identified according to the international 
ImMunoGeneTics database (IMGT) (32). In total, genes representing 4 of the 15 murine VH 
families were identified (Figure 2A). The VH chains displayed a strong bias toward the use 
of the VH1 family (74%), which represents approximately 50% of the VH gene repertoire 
available and is located most distal from the diversity genes (45–47). Within the four VH 
families, the VH genes included 14 of the possible 92 functional C57BL/6 VH genes (46), of 
which IGHV1-82*01 was the most common (26%), followed by IGHV5-4*01 (13%) 
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(Figure 2B). The DH segment of IgH most frequently employed was the DH1-1*01 gene 
(37%) (Figure 2C). For the JH gene segment, genes 1–4 were used with similar frequencies, 
ranging from 20–30% each (Figure 2D).
Because C57BL/6 mice predominately use the kappa light chain (45), and preliminary 
experiments confirmed that the anti-HA response in our experiments was comprised of 85–
90% kappa light chain usage (data not shown), we only amplified these VL chains. Of the 18 
known VK families, 10 (55.5%) were identified in our screen with a bias toward use of the 
VK14 family (36%) (Figure 2E). VK3 and 4 were also well represented, with 24% and 16% 
of germline sequences used, respectively. Of the possible 93 murine-expressed VK genes, 19 
were recovered from the HA-specific B cells (20%) (Figure 2F), and of these, segment 
IGKV14-130*01 was obtained most frequently (26%), followed by IGKV3-4*01 and 
14-11*01 (10% each). All four possible IgL J genes were used, with JK5 represented most 
often (44%) (Figure 2G).
Germ-line gene combinations and CDR3 sequence analysis of the IgH and IgL chain anti-
HA repertoire
The 54 individual anti-HA IgH chains included 32 distinct VDJH combinations, with 11 
being employed multiple times (from 2–6 times) (Figure 3A). The length of the CDR3 
region (produced through joining the 3’ end of VH, a D segment, and the 5’ end of JH) 
ranged from 8 to 17 amino acids (Figure 3B). As well as a number of identical CDR3 
sequences, clusters of similar CDR3 sequences were observed, mainly but not solely driven 
by similar VDJ usage (Figure 3A). For example, the sequence C[T/A][T/
S]GGSSGYGGAYW was seen 5 times, and was generated by the use of the same V, D, and 
J gene segments (14-4*01, 3-2*02, and 3*01 respectively), while the sequence 
CVRRGDYYFDYW, identified twice, was generated from either 1-50*01/1-1*02/3*01 or 
1-50*01/1-3*01/2*01 V/D/J regions.
The 50 IgL chains encode 25 unique VJL combinations, 12 of which were represented 
multiple times (from 2–9 instances) (Figure 3C). For IgL, the CDR3 region is formed by the 
3’ end of VL and the 5’ end of JL. The length of the IgL CDR3 ranged from 8 to 11 amino 
acids, with 90% encoding 9 residues (Figure 3D). The VL CDR3 sequences were less 
diverse than those of VH, with three major clusters identified, including 9 that had identical 
sequences (Figure 3C). As with IgH, some evidence for convergence on sets of CDR3 
sequences was observed. Similar CDR3 sequences were usually generated by identical V/J 
germline usage (e.g., 9 instances of CLQFYEFPLTF generated by 14-130-01/5*01), but in 
some cases, similar CDR3 sequences were generated by different V and J germlines 
(CQQS[K/N]E[V/D]P[L/W]TF generated by 3-2*01/5*01 or 3-4*01/1*01).
In 18 cases we amplified both the IgH and IgL chain from the same B cell, allowing analysis 
of the complete antibody gene segment utilization (Table 2), as well as the cloning of an 
rmAb for functional analysis. In some cases (e.g., 146-D11 and 146-C07), the use of a 
similar IgH sequence (CDR3: CT[T/S]GGSSGYGGAYW, V/D/J : 14-4*01/3-2*02/3*01) 
and an identical light chain (CDR3: CQQWSSNPPTF,V/J: 4-59*01/2*01) suggests that 
these samples may represent clonal expansion and somatic mutation of a single naïve B cell. 
However, rmAb 046-D11, with the same IgH CDR3 and V/D/J usage as 146-D11 and 146-
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C07, was paired with a different light chain (CDR3 sequence CLQFYEFPLTF, 
14-130-01/5*01 V/J). Similarly, within IgL sequences, the IGKV14-130*01/IgJ5*01 
combination was seen most often (18% of sequences: Figure 3C), but of the three rmAb with 
this IgL sequence (046-D11, 069-A09, and 139-22a: Figure 3C and Table2), each was paired 
with a different IgH, showing that these were not produced by clonal expansion and again 
supporting the notion of convergence upon a common paratope.
Diversity of the anti-HA antibody response
Our sample contained 32 different VDJ sequences among 54 total heavy chain sequences, 
and 25 different VJ sequences among 50 total light chain sequences. We used several 
approaches (37–44) to predict the overall germline sequence diversity within the anti-HA 
immunoglobulin response, based on the numbers of repeated (“recaptured”) sequences in 
our sample. The algorithms consistently inferred that our sample drew from a pool of 72-130 
different heavy chain VDJ combinations, and 35 light chain VJ combinations (Table 3).
Generation of mouse-human chimeric antibodies
In eighteen cases, we cloned both an IgH and an IgL variable region from the same 
individual B cell (Table 2). All except two (146-C07 and 146-D11) were unique in terms of 
germline IgH and IgL combinations. When sorting single B cells by flow cytometry, we 
selected IgG-expressing rather than IgM-expressing cells. Since this population has 
undergone class switching, they should be dominated by memory cells and likely contain 
some level of somatic mutation in the IgH and IgL regions. Varying levels of somatic 
mutation, at the amino acid level, were present in these genes (0–15 mutations for H and 0–8 
for L) (Table 2, “Δ”). Only one rmAb (065-C06) retained germline sequence in both IgH and 
IgL, indicating that as expected most antibodies had undergone some amount of affinity 
maturation during the infection and vaccine boost.
The matched IgH and IgL chains were cloned into a vector supplying an IgG1 human 
constant region (heavy chain) or human kappa constant region (light chain), as well as the 
IL2 signal sequence and promoter elements to allow expression in mammalian cells. For 16 
of the pairs, co-expression of the IgH and IgL chains in 293T cells resulted in secretion of 
recombinant monoclonal antibodies (rmAb), which migrated at approximately 150 kDa 
when subjected to SDS-PAGE, the same size as a control Ig (data not shown). Two of the 
antibody IgH/IgL pairs (065-C09 and 065-D10) did not efficiently assemble into full-sized 
mature Ig, and predominately showed bands of an apparent molecular mass of 50 and 25 
kDa (data not shown); therefore, these pairs were not analyzed further. The concentration of 
each rmAb was determined by ELISA and normalized by concentrating the tissue-culture 
supernatant to approximately 25 μg/mL.
Most cloned Igs recognize influenza hemagglutinin
The 16 rmAb were screened for reactivity by ELISA using the 2011/12 TIV as antigen. In 
total, 15 of the rmAb reacted with TIV (defined as a signal greater than twice background 
level, at ≤25 μg/mL), and 10 of these bound at a concentration of <1 μg/mL (Table 4), 
indicating that the sorting process isolated B cells that do in fact target HA.
Wilson et al. Page 8













The rmAb were further characterized by ELISA for reactivity to the individual viruses that 
were components of the TIV. Eleven of the rmAb were reactive with the monovalent vaccine 
containing the HA from CA/07(H1pdm), while none reacted with inactivated BR/60(B) 
(Table 4). Four rmAb were also reactive with inactivated VIC/210(H3), although for three 
rmAb (145-D11, 146-B09 and 146-D11) this reactivity was only seen at the highest 
concentration tested. The fourth rmAb (065-C11) was strongly reactive with VIC/210(H3) 
as well as CA/07 (H1pdm) (Table 4), suggesting that it is a subtype cross-reactive antibody.
Cloned Igs recognize H1 with high affinity
BioLayer interferometry (BLI) was performed on the 11 rmAb with the highest binding 
activity toward H1N1pdm by ELISA analysis, to determine the relative binding rate 
constants to recHA of CA/07(H1pdm). Two rmAb (065-C11 and 069-B03) did not bind 
detectably bind recHA in this assay, while the nine remaining rmAb bound recHA with 
similar association rates, surpassing that of the control Ab (Figure 4A). These nine rmAb 
can be divided into two categories based on dissociation rates: those ranging from 8 x 
10−6(1/s) to 3.7 x 10−5(1/s) (065-C05, 065-D01, 139-22a, 154-C09, 145-D11, 146-C07 and 
164-D11) and a second with faster dissociation rates ranging from 4.9 x 10−5(1/s) to 1.4 x 
10−4(1/s) (069-A09, 145-C09 and 146-B09) (Figure 4B). As the rmAb association rates 
were similar, each group also has similar steady state affinities, of about 2 x 10−11 to 6.4 x 
10−11 KD for the first group and 7.8 x 10−10 to 2.6 x 10−9 KD for the second (Figure 4C). 
Interestingly, 065-C11, an antibody that displayed strong reactivity with the TIV as well as 
with the individual H1N1pdm and H3N2 virus components of the TIV in ELISA (Table 4), 
failed to detectably bind to recombinant H1pdm in this assay.
Cloned Igs are able to inhibit hemagglutination
We also tested the ability of the 16 rmAb to block hemagglutination of CA/07(H1pdm) 
viruses. The HI assay is widely used to measure influenza post-infection and post-
vaccination antibody responses that are biologically meaningful, since HI titers ≥32 or 40 
are correlated with protection against influenza infection (5). All 9 rmAb that were strongly 
reactive in the recHA BLI assay also showed HI activity against the CA/07(H1pdm) virus at 
concentrations ranging from 0.098 to 0.78 μg/mL (Table 4). Only 145-D11, a rmAb that was 
weakly reactive with VIC/210(H3) by ELISA, showed HI activity against VIC/210(H3) 
virus, and then only at 12.5 μg/ml. 065-C11, which showed binding activity toward TIV in 
ELISA assays (Table 4) but no reactivity to the recHA in BLI (Figure 4), also lacked HI 
reactivity. All rmAb failed to inhibit hemagglutination of BR/60(B) (Table 4).
ELISA activity against H1N1 recHA’s
Having established that the panel of rmAb display only limited cross-clade reactivity, we 
further tested the ability of the eleven rmAb reactive to the H1pdm vaccine component 
(Table 4) to bind a set of recHA within the H1 lineage. The amino acid identities of each 
HA, compared to OH/07, are shown in Table 1, and range from 80% (BR/59) to 86% (SC/
1918 and IA/1930). As a control we also included HA from the H13 lineage (DE/68).
All but 065-C11 bound to the full length recHA from CA/04(H1pdm). Consistent with the 
HI activity of these rmAb, the same rmAb also bound to the HA1 domain of CA/04. Three 
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rmAb (065-D01, 069-A09 and 139-22a) also showed reactivity with the recHA of SC/1918, 
at levels comparable to that of CA/04 (Table 5). 065-D01 further reacted with the recHA of 
IA/1930, although at >200 fold increased concentration. None of the rmAb bound detectably 
to recHA from Bris/59. The rmAb 065-C11, which efficiently bound to both H1N1pdm09 
and H3N2 vaccine antigen but failed to bind recHA in BLI analysis, also failed to bind 
recHA in the more sensitive ELISA assay. This suggests the 065-C11 rmAb may recognize a 
cross-reactive conformational epitope present in virus-associated HA that is not preserved in 
the recHA used for ELISA assays.
Discussion
The antibody response to HA following influenza virus infection or vaccination includes a 
wide range of specificities. Some antibodies bind to highly strain-specific regions and confer 
protection, others bind to conserved regions that can lead to varying degrees of cross-
reactive protection, and some may bind to HA without neutralizing the virus in vitro, 
although in some cases (though not all (8, 48)) such antibodies may confer some protection 
in vivo (49). Although antibodies with these different specificities and functions can be 
measured using different assays (e.g. ELISA, microneutralization (MN), and HI), the 
relative proportion of antibodies with each type of specificity and function that is stimulated 
by a given exposure event is unclear. In this study, we isolated mouse memory B cells 
specific to influenza H1pdm HA, analyzed individual IgH and IgL genes to characterize the 
genetic diversity of the response, and produced recombinant antibodies to analyze specificity 
and binding kinetics. Although there are some molecular differences between mouse and 
human antibodies, in general the B cell response is similar in the two species. Because 
humans are typically repeatedly exposed to multiple strains of influenza throughout their 
lifetime, leading to unpredictable expansion of particular B cell clones depending on the 
precise history of virus exposure, the mouse is a simpler model that can be used to assess 
antibody responses to the virus.
Overall, the anti-HA antibody response generated in these mice was relatively constrained. 
The 54 heavy chain variable genes analyzed in our sample included 14 different VH genes 
(representing 4 different families), while the 50 light chain variable regions included 19 
different VK genes from 10 different families. We infer that our samples drew from a 
population of approximately 72–130 different heavy chain VDJ combinations, and 
approximately 35 different light chain VJ combinations. This suggests that there must be 
considerable redundancy in the germline usage for the anti-HA response, as previously 
proposed based on studies of anti-HA monoclonal antibody repertoire (50, 51). This 
inference assumes that the purification of the HA-specific B cells and cloning of variable 
regions was unbiased, and that relevant anti-HA antibodies raised against virion-associated 
HA will bind to recombinant HA. However, while it is difficult to validate this without 
already knowing the global anti-HA repertoire, sorting was performed using the full HA 
ectodomain and PCR primers covered the full range of heavy and kappa light chain 
sequences, so there is no a priori reason to expect bias. Considering the further diversity 
contributed by heavy/light chain pairing, junctional diversity, and somatic hypermutation, 
the actual pool of H1pdm anti-HA antibody repertoire must be significantly larger than these 
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estimates, roughly consistent with the BALB/c PR8 anti-HA paratypic repertoire of 
approximately 1500 specificities estimated by Staudt and Gerhard in 1983 (51).
CDR3 regions are generally a principal determinant in antigen molecule binding specificity 
(52, 53). IgH chain CDR3 sequences showed some redundancy, while the IgL CDR3 
repertoire was less diverse, suggesting that a limited number of CDR3 sequences (especially 
in IgL) are preferred for binding to H1pdm HA. The fact that very similar CDR3 sequences 
were generated from different IgH V/D/J IgL V/J combinations also suggests convergence 
on a specific set of CDR3 sequences. The lower diversity seen in the IgL germline usage and 
CDR3 sequences compared to IgH (Figure 3A vs. 3C) may imply that the IgL region is more 
important than the IgH region in determining binding specificity, and is therefore more 
constrained.
The analysis of 16 paired IgH/IgL chains, each derived from a single B cell (i.e. variable 
regions from the natural antibody), indicated that the majority of these Igs (15 out of 16) 
were indeed specific to the boosting antigen, in that they were capable of binding TIV in 
ELISA assays. Of these, 10 rmAb bound to inactivated CA/07 at low concentrations (<31 
ng/mL), and 9 bound recHA with high affinity (>10−9 K). However, these assays may 
underestimate HA binding to B cells because previous studies have shown that B cell Igs 
that are capable of binding HA when expressed on the surface of a B cell (as membrane-
bound molecules) may have low affinity or fail to bind to HA when expressed as secreted 
antibodies in the germline form (54). In particular, this may explain the poor binding activity 
of 065-C06, a rmAb that maintained strictly germline identity. This rmAb, as a soluble 
human/mouse chimeric molecule, bound TIV only at the highest concentration tested by 
ELISA. In addition, it is possible that the use of human constant regions for these mouse 
variable regions may have led to some changes in activity. For example, 2 of the cloned 
IgH/IgL pairs failed to assemble when expressed in the context of the human constant 
regions (Table 2 and data not shown), even though they were derived from a single B cell 
and presumably capable of effective assembly in vivo.
As well as binding to inactivated virus, 9 of 16 rmAb bound recHA1 (the globular head of 
HA) and were active in HI assays. Thus, >50% of the cloned antibodies have the ability to 
inhibit virus receptor binding, a function of neutralizing and protective antibodies (55).
Three rmAb further showed subtype-specific cross-reactivity with the antigenically related 
recHA of SC/1918, and one also reacted weakly with IA/30; none reacted with the recent 
seasonal H1N1 virus BR/59. These viruses share just 73–83% identity to OH/07 in the HA1 
region; however, specific antigenic sites are more similar. For example, the Sa region of SC/
1918 is 92% identical to OH/07, and previous studies have identified cross-reactive 
antibodies isolated from humans that target this region (56). Four of the antibodies showed 
some cross-reactivity with H3N2, although three of these reacted only weakly. One of these 
also had HI activity against H3N2, although again, this activity was only detected at high 
concentrations. This is not surprising as the B cells were sorted based on the ability to bind 
recHA of H1pdm, which shares only 43% AA identity with HA of VIC/210. Further, a lack 
of H3 HA cross-reactivity is likely due to the timing of splenocyte harvest (day 3 post TIV 
boost). Interestingly, the rmAb with the most cross-reactivity in ELISA using inactivated 
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vaccine (Table 4, 065-C11) did not show detectable HI activity against any virus, nor did it 
react with recHA in BLI or ELISA assays. This rmAb failed to react with the distantly-
related influenza B virus, suggesting that the broad influenza A cross-reactivity is specific. 
These findings suggest that 065-C11 may react with a conserved, conformationally sensitive 
epitope on HA and future experiments will aim to identify this interaction. Thus, although 
some cross-subtype reactivity was identified in our characterization, the cross-reactivity was 
weak and poorly associated with HI activity.
In conclusion, these findings suggest that the antibody recall response to HA following 
H1N1pdm infection and vaccination of naïve animals is diverse, but based on a relatively 
limited number of germline sequences. The majority of cloned antibodies are directed 
against the globular head of HA and exhibited HI activity and are therefore likely capable of 
protecting against influenza disease in vivo. A subset of these antibodies further showed 
subtype-specific cross-reactivity with the antigenically related recHA of SC/1918 while 
minimal subtype cross-reactivity was identified. Further studies with this approach will help 
delimit the diversity of the antibody repertoire profile in response to novel vaccination 
strategies, with the goal of identifying approaches that induce a high yield of broadly 
reactive and neutralizing antibodies.
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Figure 1. Flow cytometry of splenocytes from mice immunized with H1pdm
C57BL/6 mice were immunized with H1N1pdm09 virus and boosted with TIV as described. 
Splenocytes from naïve mice (A, B) or immunized mice (C,D) were stained with a cocktail 
of antibodies including CD19, and with H13 as a control (A,C) or H1pdm (B,D). 
Splenocytes were gated as described to show the percent of HA-specific B cells.
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Figure 2. IgH and IgL germline usage
HA-specific B cells were sorted and IgH and IgL variable regions were amplified from 
individual B cells and sequenced. Germline usage was determined using the international 
ImMunoGeneTics database of mouse immunoglobulin sequences. Usage of VH gene 
families (A), VH genes (B), DH genes (C), JH genes (D), VK gene families (E), VK genes 
(F) and JK genes (G) are shown as a percentage of total heavy or light chain sequences 
respectively.
Wilson et al. Page 17













Figure 3. IgH V, D and J IgL V and J gene combinations and CDR3 sequences
CDR3 sequences were aligned using MUSCLE [1] and a maximum likelihood dendrogram 
was generated using MEGA5 for IgH (A) and IgL (C). Columns indicate the IgH or IgL 
identifier (“ID”), the CDR3 sequence (CDR3), and the identity of the V, D, and J (IgH) or V 
and J (IgL) gene segments used. “*” indicates the segment was sequenced but not cloned. 
The overall distribution of IgH (B) and IgL (D) CDR3 length.
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Figure 4. Biolayer interferometry analysis of binding kinetics
BioLayer Interferometry (BLI) using an Octet Red instrument (Fortebio) was performed as 
described. The association rate (Kon) (A), dissociation rate (Kdis) (B), and the steady state 
affinity (KD) (C) were calculated for each rmAb. Error bars represent the standard deviation 
generated by running multiple rmAb concentrations.
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Table 3
IgH and IgL diversity estimates
The “SPECIES” module for R was used to estimate the diversity of the combinations of germline V, D, and J 
segments (IgH chain) or V and J segments (light chain) in the population of antibodies specific for HA, based 
on sampled IgH and IgL sequences. Estimates and 95% confidence intervals (CI) are shown for each method.
VDJ (H) VJ (L)
Estimate 95% CI Estimate 95% CI Reference
113 55–321 35 29–60 Chao (1984)
75 47–148 38 30–60 Chao & Lee (1992) (ACE method)
92 51–223 38 29–63 Chao & Lee (1992) (ACE-1 method)
72 40–171 35 28–60 Chao & Bunge (2002)
111 63–159 39 29–49 Burnham & Overton (1978), Burnham & Overton (1979)
129 47–251 38 28–80 Wang & Lindsay (2005)
97 63–114 37 32–71 Wang (2010)
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